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Abstract: The study investigates pentosidine levels, an advanced glycation end-product, in patients with erosive and non-
erosive hand osteoarthritis (HOA) and determine its potential association with clinical findings and imaging-defined joint 
damage. 
Pentosidine was measured by HPLC in serum and urine of 53 females with HOA (31 erosive and 22 non-erosive HOA) 
and normalised to the total serum protein or urinary creatinine, respectively. Pain, joint stiffness and disability were 
assessed by the Australian/Canadian OA hand index (AUSCAN). The hand radiographs scored according to the Kallman 
grading scale were assessed to determine a baseline value and reassessed after two years. 
The levels of urine pentosidine, but not of serum pentosidine, were higher in patients with erosive HOA than in non-
erosive HOA (p=0.039). Urinary pentosidine correlated with CRP (r=0.302, p=0.031), ESR (r=0.288, p=0.041) and 
AUSCAN (r=0.408, p=0.003). Serum pentosidine, but not in urine, significantly correlated with the Kallman radiographic 
score in erosive HOA at the baseline (r=0.409, p=0.022) and after 2 years (r=0.385, p=0.032). However, when corrected 
for age and disease duration, only correlation between urine pentosidine and AUSCAN remained significant (r=0.397, 
p=0.004). 
Our data suggest that serum and urine pentosidine levels may relate to the distinctive clinical and morphological features 
of HOA. 
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INTRODUCTION 
  Osteoarthritis (OA) is the most prevalent rheumatic joint 
disease, and it affects approximately 15% of the population [1]. 
The disease occurs and causes disability mostly among elders; 
however, hand OA (HOA) is also prevalent in middle-aged and 
post-menopausal women [2]. HOA is considered to be a subset 
of primary generalised nodal OA. HOA, particularly its erosive 
subset, is associated with substantial pain, stiffness and physical 
disability, which may be similar to those symptoms seen in 
patients with rheumatoid arthritis (RA) [3]. Erosive HOA is 
characterised by prominent local inflammation of hand joints, 
leading to central erosions of the distal and, less frequently, of 
the proximal interphalangeal joints [4]. Routine blood tests are 
not helpful, and no biomarker is currently of any specific value 
for monitoring or predicting OA in an individual patient. 
  The pathogenesis of OA is still unclear. However, the 
age-associated accumulation of advanced glycation end-
products (AGEs) in joint tissues has been shown to 
contribute to molecular changes and pathologic alterations in 
articular cartilage, which then may be more susceptible to 
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damage and development of OA [5-7]. Pentosidine was 
characterised as a sensitive marker for all AGEs and was 
demonstrated to have increased levels in the articular 
cartilage [7, 8]. In our previous study, we demonstrated the 
presence of increased serum levels of pentosidine in patients 
with knee OA in comparison to healthy controls, and we 
found a positive correlation between the levels of 
pentosidine and of cartilage oligomeric matrix protein 
(COMP), a marker of articular cartilage damage [9]. More 
recently, we also identified pentosidine as a potential marker 
with predictive value for radiographic joint damage in 
patients with knee OA [10]. 
  Based on our previous data, we were curious to explore 
the association between pentosidine levels and hand OA. In 
the present study, we therefore investigated levels of serum 
and urine pentosidine in female patients with erosive and 
non-erosive HOA and characterised their potential 
association with clinical findings and radiographic joint 
damage over time. 
MATERIALS AND METHODOLOGY 
Patients 
  The patients in this study were selected from the group of 
patients who had undergone radiographs of both hands at a 
baseline and again after two years in our previous studies Pentosidine May Reflects Clinical and Morphological Signs of Hand Osteoarthritis  The Open Rheumatology Journal, 2012, Volume 6   65 
[11,12]. Altogether, 53 female patients that fulfilled the 
American College of Rheumatology (ACR) criteria for HOA 
[13] were included, 31 with the erosive and 22 with the non-
erosive disease. The erosive disease was characterised 
according to the radiographic criteria published by Pattrick 
[14]. All patients were assessed for pain and effusion upon 
palpation, deformity and deviation. The Australian/Canadian 
OA hand index (AUSCAN) and Dreiser algo-functional 
index, a 10-item investigator-administered questionnaire, 
were evaluated [15, 16]. None of the patients had diabetes 
mellitus and/or renal disease that could influence the 
pentosidine levels. This study was designed in accordance 
with the Declaration of Helsinki (2000) of the World 
Medical Association and approved by the local ethical 
committee. All the participating patients signed informed 
consent. Their demographic data are summarised in Table 1. 
Laboratory Analysis 
  Venous blood was drawn from all patients at the time of 
the urinary sample collection. Vacutainers with blood 
samples were centrifuged at 2000 rpm (600 g) for 10 
minutes, and serum and urine samples were stored at –20°C 
until the time of analysis. 
  Pentosidine levels were measured in serum and urine 
samples by high performance liquid chromatography 
(HPLC) combined with sensitive fluorescent detection. Due 
to very low concentrations of pentosidine and complexity of 
the analyzed material, previous sample pretreatment was a 
necessary step. The samples were hydrolysed for 16 hours at 
105°C in an aliquot of 35% HCl, the hydrolysate was 
purified and preconcentrated by solid phase extraction using 
the self-made purification columns filled with microgranular 
cellulose and the n-butyl alcohol/ acetic acid system was 
applied. The pentosidine-containing fraction was then 
desorbed with 0.05 mol/l hydrochloric acid, the extract was 
evaporated and the residue was reconstituted in a mobile 
phase containing 0.02 mol/l heptafluorobutyric acid, 0.01 
mol/l ammonium sulphate and acetonitrile (linear gradient 
12.5 – 25.0 % in 20 minutes). After this procedure the 
sample was applied into a thermostated (40°C) C18 reversed 
phase separation column (Separon SGX C18, 150x3 mm 
from Tessek; Prague, Czech Republic) of the HPLC system 
(Shimadzu, LC-10ADvp; Kyoto, Japan). The 
chromatographic system operated by the CLASS VP 
software enable the gradient flow of the mobile phase (flow 
rate 0.5 ml/ min.) and sensitive fluorescent detection 
(excitation/ emission wavelengths  = 335/385 nm). Length 
of one chromatographic run was 30 minutes. 
  Pentosidine standard is not commercially available, so 
the synthetic pentosidine standard used for calibration was 
prepared in our laboratory by a modified version of the 
procedure kindly provided by Prof. V. M. Monnier (Case 
Western Reserve University, Cleveland, OH, USA) which is 
based on the unique polymer-analogical non-enzymatic 
reaction (using polymer form of lysine and the proper 
carbohydrates). The quantity and purity of the prepared 
Table 1.  Demographic and Clinical Characteristics of Patients with Erosive and Non-Erosive Hand Osteoarthritis (HOA) 
 
Characteristics  Erosive HOA (n=31)  Non-Erosive HOA (n=22)  p 
Age (years)  65.55 ± 8.15  63.09 ± 10.85  0.551 
Sex (females/ males)  31/0  22/0  - 
Disease duration (years)  8.94 ± 7.74  7.16 ± 4.84  0.650 
CRP (mg/l)  1.81 ± 1.15  1.79 ± 1.77  0.378 
ESR (mm/1
st hour)  13.26 ± 8.82  14.43 ± 9.10  0.530 
AUSCAN total   41.55 ± 11.89  32.32 ± 10.17  0.003 
Dreiser algo-functional index   18.45 ± 4.77  14.95 ± 4.67  0.005 
Physical Examination (Mean Count of Affected Joints ± SD)          
Deformity  11.84 ± 4.12  8.32 ± 4.74  0.008 
Deviation  4.32 ± 3.05  1.09 ± 1.95  <0.001 
Tenderness  9.16 ± 4.03  5.09 ± 3.31  <0.001 
Effusion  4.39 ± 4.15  1.68 ± 2.17  0.014 
Radiographs         
Baseline Kallman score   58.90 ± 28.89  26.14 ± 18.57  <0.001 
Kallman score at year 2  61.39 ± 28.67  26.73 ± 19.16  <0.001 
Progression (difference from baseline to year 2)  2.48 ± 3.13  0.59 ± 1.59  0.002 
Presence of knee OA (%)  70.0  59.1  0.425 
Three Phase Bone Scintigraphy         
Blood pool (count of inflamed joints)  3.90 ± 3.24  1.45 ± 2.14  0.002 
Late phase (count of remodelled joints)  14.77 ± 6.28  6.00 ± 5.99  <0.001 
Legend: n = number of patients, p = statistical significance, CRP = C-reactive protein; ESR = Erythrocyte Sedimentation Rate, AUSCAN = Australian/Canadian Osteoarthritis Hand 
Index, HOA = hand osteoarthritis. The data are expressed as the mean ± SD, unless stated otherwise. 66   The Open Rheumatology Journal, 2012, Volume 6  Braun et al. 
standard was assessed by Dr. D. Sell (the same affiliation). A 
detailed description of the method was published earlier [17, 
18]. 
  The urine pentosidine (U-PEN) levels were normalised to 
the creatinine levels to account for differences in urine 
concentrations, and the serum pentosidine (S-PEN) levels 
were normalised to the levels of total serum protein. The 
high sensitivity C-reactive protein (hsCRP), total serum 
protein and urinary creatinine levels were measured by 
standard biochemical methods using the biochemical 
analyser Olympus (model AU 400, Japan). 
Imaging 
  Each patient underwent posteroanterior plain radiographs 
of both hands at a baseline period and again after two years. 
Radiographs were scored by a trained reader according to the 
Kallman grading scale [19]. Individual joints were assessed 
for the presence of osteophytes (graded 0-3), joint space 
narrowing (0-3), subchondral sclerosis (0-1), subchondral 
cysts (0-1), lateral deformity (0-1), and the collapse of a 
central joint cortical bone (0-1). To exclude the impact of 
knee OA on the levels of serum pentosidine, radiographs of 
both knees were performed to obtain baseline images. 
  To evaluate the inflamed hand joints and bone 
remodeling, blood pool (second phase) images and late (third 
phase) images of the three-phase bone scintigraphy were 
performed following a bolus injection of 600 MBq of Tc-
99m methylene disphosphonate into an antecubital vein. All 
of the planar anterior images that were focused on the small 
hand joints were interpreted by the same radiologist. Hand 
joints were considered inflamed when the blood pool images 
indicated increased indicator uptake. Osteoblastic activity 
representing bone remodeling was established by increased 
indicator uptake in the late phase. For the purpose of this 
study, the total number of positive joints was calculated. 
Statistical Analysis 
  Statistical analysis was done using GraphPad Prism 5 
(GraphPad Prism Software Inc.) and SAS statistical software 
(version 9.2; www.sas.com). For comparison between the 
two groups, Mann-Whitney test was used. The results were 
expressed as the mean ± standard deviation (SD). 
Significance level 0.05 was used. Nonparametric analysis of 
correlations was performed, when variables were not 
normally distributed, using Spearman correlation coefficient 
(r) or partial Spearman correlation coefficients (rho). 
Multivariate correlation analysis of dependence between 
variables of interest (U-PEN, S-PEN, Kallman scores, CRP, 
ESR) was performed, and partial Spearman correlation 
coefficients were computed, adjusted for both age and 
disease duration. 
RESULTS 
  This study was designed to particularly recruit patients 
with erosive HOA; therefore more patients with the erosive 
disease than with the non-erosive disease were enrolled in 
this study. The patients in the two groups did not 
significantly differ in terms of age, sex, disease duration, 
acute phase reactants or the presence of knee OA (Table 1). 
However, patients with the erosive disease used more non-
steroidal anti-inflammatory drugs (NSAIDs), had more 
tender and swollen joints, had more deformities and 
deviations, and had more joint damage and inflammation as 
assessed by hand radiographs and scintigraphy than the 
patients with the non-erosive disease (Table 1). 
Pentosidine and Clinical Findings 
  The levels of serum pentosidine that were normalised to 
the total protein content in patients with erosive HOA were 
comparable to those in patients with the non-erosive disease 
(1.06±0.61 vs 0.95±0.34 nmol/g; p=0.678) as shown in Fig. 
(1A). On the other hand, the urinary levels of pentosidine 
that were normalised to the urinary creatinine concentrations 
were significantly higher in erosive than in non-erosive HOA 
(2.69±1.66 vs 2.42±1.90 nmol/mmol, p=0.039) as shown in 
Fig. 1B). Using univariate analysis, in all patients with HOA, 
we found a significant correlation between the levels of 






Fig. (1). Serum (A) and urinary pentosidine (B) in patients with 
erosive and non-erosive hand osteoarthritis (HOA). The serum 
pentosidine levels were normalised to the levels of total serum 
protein (S-PEN/TP), and the urine pentosidine levels were 
normalised to the creatinine levels (U-PEN/cr.). The horizontal 
lines represent the median value. Pentosidine May Reflects Clinical and Morphological Signs of Hand Osteoarthritis  The Open Rheumatology Journal, 2012, Volume 6   67 
levels of urinary, but not serum, pentosidine correlated 
significantly with both CRP (r=0.302, p=0.031) and ESR 
(r=0.288, p=0.041). While the serum levels of pentosidine 
did not correlate with the measures of disease activity, pain, 
stiffness or number of swollen joints, the levels of urine 
pentosidine significantly correlated with the dimensions of 
joint pain, stiffness and disability as assessed by AUSCAN 
(r=0.408, p=0.003). However, the urine pentosidine levels 
did not correlate with the Dreiser algo-functional index. A 
trend of association between the urinary pentosidine levels 
and the total number of tender joints (r=0.269, p=0.054), but 
not with the number of swollen joints (r=-0.142, p=0.316) 
was observed. When adjusted for age and disease duration, 
correlation between urine pentosidine and AUSCAN 
remained significant (r=0.397, p=0.004) (Table 2). 
Pentosidine and Structural Joint Damage 
  Patients with the erosive disease had more severely affected 
hand joints, as assessed by both radiographs and scintigraphy, 
than those with the non-erosive disease (Table 1). As expected, 
Table 2.  Association of Pentosidine, Clinical and Morphological Features of HOA 
 
  r (before adjustment)  p (before adjustment)  Rho (after adjustment)  p (after adjustment) 
Erosive HOA         
U-PEN and CRP  0.117  0.539  0.132  0.502 
U-PEN and ESR  0.217  0.240  0.151  0.444 
U-PEN and AUSCAN  0.277  0.132  0.250  0.190 
U-PEN and K0  0.266  0.148  0.201  0.296 
U-PEN and K2  0.253  0.170  0.187  0.331 
S-PEN and CRP  -0.064  0.737  -0.108  0.585 
S-PEN and ESR  -0.035  0.853  -0.075  0.703 
S-PEN and AUSCAN  0.325  0.075  0.242  0.206 
S-PEN and K0  0.409  0.022  0.297  0.118 
S-PEN and K2  0.385  0.032  0.276  0.147 
Non-Erosive  HOA      
U-PEN and CRP  0.163  0.481  0.156  0.536 
U-PEN and ESR  0.435  0.055  0.444  0.065 
U-PEN and AUSCAN  0.303  0.183  0.139  0.571 
U-PEN and K0  -0.414  0.062  -0.261  0.281 
U-PEN and K2  -0.422  0.057  -0.277  0.251 
S-PEN and CRP  0.131  0.572  0.157  0.534 
S-PEN and ESR  0.143  0.536  0.009  0.972 
S-PEN and AUSCAN  -0.020  0.930  -0.162  0.508 
S-PEN and K0  -0.310  0.161  -0.121  0.622 
S-PEN and K2  -0.304  0.170  -0.119  0.629 
Erosive + Non-Erosive HOA          
U-PEN and CRP  0.302  0.031  0.251  0.085 
U-PEN and ESR  0.288  0.041  0.231  0.114 
U-PEN and AUSCAN  0.408  0.003  0.397  0.004 
U-PEN and K0  0.173  0.219  0.227  0.114 
U-PEN and K2  0.166  0.238  0.211  0.141 
S-PEN and CRP  0.010  0.946  -0.066  0.657 
S-PEN and ESR  0.037  0.031  -0.019  0.897 
S-PEN and AUSCAN  0.177  0.205  0.142  0.326 
S-PEN and K0  0.122  0.383  0.105  0.468 
S-PEN and K2  0.109  0.439  0.090  0.535 
Legend: p = statistical significance, HOA = hand osteoarthritis; U-PEN = urinary pentosidine; S-PEN = serum pentosidine; CRP = C-reactive protein; ESR = Erythrocyte 
Sedimentation Rate; AUSCAN = Australian/Canadian Osteoarthritis Hand Index; K0 = Baseline Kallman score; K2 = Kallman score after 2 years; r = Spearman correlation 
coefficients (without adjustment to age and disease duration); rho = Spearman partial correlation coefficients corrected to age and disease duration. 68   The Open Rheumatology Journal, 2012, Volume 6  Braun et al. 
the mean radiographic progression and scintigraphic 
progression over a period of two years were much faster with 
the erosive than with the non-erosive disease (Table 1). In all 
patients with HOA, the levels of serum and urine pentosidine 
did not correlate with the baseline joint radiographic damage 
(r=0.122, p=0.383 and r=0.173, p=0.219; respectively) or with 
the damage observed after two years (r=0.109, p=0.439 and 
r=0.166, p=0.238; respectively). However, in a subgroup of 
patients with the erosive disease, the levels of serum pentosidine 
significantly correlated with the Kallman baseline radiographic 
score and with the score determined after 2 years (r=0.409, 
p=0.022 and r=0.385, p=0.032; respectively) as shown in Fig. 
(2). On the contrary, urinary pentosidine levels did not correlate 
with the baseline Kallman radiographic score or with the 
radiographic score determined after 2 years (r=0.266, p=0.148 
and r=0.253, p=0.170; respectively), and this association was 
also not found in patients with the non-erosive disease in 






Fig. (2). Correlations of S-PEN with Kallman radiographic 
scores in HOA: (A) baseline, (B) after two years. The shown 
graphs were constructed from the data without adjustment to age 
and disease duration. Abbreviations: S-PEN/TP = serum 
pentosidine levels normalised to the levels of total serum protein; 
HOA = hand osteoarthritis; r = Spearman correlation coefficient;   
p = statistical significance. 
and disease duration, correlation between serum pentosidine and 
radiographic scores remained no longer significant (Table 2). 
The levels of serum and urinary pentosidine in both groups of 
patients were not associated with the number of joints positive 
for blood pool phase and late phase scintigraphy (data not 
shown). 
DISCUSSION 
  In the present study, we demonstrate for the first time higher 
levels of urine pentosidine, but not of serum pentosidine, in 
patients with erosive than in those with non-erosive hand OA. 
Additionally, the urine levels of pentosidine corrected for age 
and disease duration correlated significantly with assessments of 
joint pain, stiffness and disability in patients with HOA. 
  The levels of pentosidine were previously shown to be 
increased mostly under the conditions of inflammation, and they 
were associated with the laboratory and clinical disease activity 
in patients with RA [8, 20, 21]. Patients with OA have 
significantly lower levels of urine pentosidine than those with 
RA [20]. Although the levels of CRP were within the normal 
range in both groups of HOA patients, we found a positive 
correlation between the urinary pentosidine levels and acute 
phase reactants in patients with HOA. However, we did not 
observe this association with the levels of serum pentosidine, 
which is concurrent with two recent studies showing that the 
levels of serum pentosidine and other AGEs do not always 
reflect the disease activity in patients with RA [22, 23]. Our data 
also show that the levels of urinary pentosidine are related to the 
measurements of joint pain, stiffness and disability that were 
assessed by AUSCAN in patients with HOA. On the other 
hand, the levels of urinary pentosidine did not correlate with the 
degree of radiographic changes of finger joints. This may be 
consistent with recent data showing that urinary pentosidine 
levels do not correlate with radiographic changes in large joints 
[24] and do not predict knee cartilage loss in patients with knee 
OA [25]. 
  The non-enzymatic glycation of proteins such as collagen or 
aggrecan in articular cartilage contributes to the formation of 
AGEs. This process is associated with ageing and results in 
increased cartilage stiffness, increased degradation of 
extracellular matrix proteins and decreased proteoglycan 
synthesis by chondrocytes [5]. Even though the presence of 
AGEs in articular cartilage is not specifically related to OA, the 
age-related accumulation of AGEs in the cartilage is likely to 
play a role in the pathogenesis of the disease [5-7, 26]. 
Pentosidine represents an adequate marker for all AGEs, and it 
is found in articular cartilage, serum, urine and synovial fluid 
[7-10, 17, 18, 20-22, 25]. Recently, urinary pentosidine levels 
were found to be elevated in patients with knee and hip OA in 
comparison to healthy control group individuals [18]. We also 
reported elevated levels of serum pentosidine in patients with 
knee OA and an association between the levels of pentosidine, 
the local cartilage degrading marker COMP and radiographic 
knee joint damage [9, 10]. Furthermore, the non-enzymatic 
glycation of collagen type I and the accumulation of pentosidine 
are also associated with osteoporosis and can induce the 
deterioration of bone quality [27]. Although we found no 
difference in the levels of serum pentosidine between patients 
with erosive and non-erosive HOA, we observed a significant 
association between the levels of serum pentosidine and 
radiographic changes in patients with the erosive disease. It can Pentosidine May Reflects Clinical and Morphological Signs of Hand Osteoarthritis  The Open Rheumatology Journal, 2012, Volume 6   69 
be therefore hypothesised that the levels of pentosidine may 
reflect the progressive bone and cartilage damage in erosive 
HOA. In that sense, our results may be similar to the recent 
finding of the C-terminal cross-linking telopeptides of type I 
collagen being correlated with the radiographic changes in 
patients with erosive HOA [28]. Because systemically measured 
pentosidine and other circulating biomarkers reflect whole body 
cartilage or bone degradation, they may be related to the 
severity of all joints affected by OA. Moreover, when the serum 
pentosidine was corrected for age and disease duration, its 
association with the degree of joint damage was no longer 
significant. These limitations have to be considered while 
interpreting the results of this and other studies. 
CONCLUSIONS 
  In conclusion, the results of this study demonstrated 
increased levels of urine pentosidine in patients with erosive 
hand OA in comparison to those with non-erosive disease and 
suggested that the urine pentosidine is related to subclinical 
inflammation and measures of joint pain, stiffness and disability 
in patients with hand OA. Further studies are necessary to show 
whether pentosidine can be used as a surrogate marker of 
severity in age-related diseases such as OA. 
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